← Leaderboards
Dat Quoc Tran
University Of Texas Hlth Sci Ctr Houston
$1,871,805
Attributed
$1,871,805
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $384.5K · FY2012–16$500K$375K$250K$125K$0
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$1,871,805 · 1
By mechanism
R01$1,871,805 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Sci Ctr Houston
Same institution · by research overlap
- Pamela Lynn Wenzel$4,442,630
- Yuying Liu$1,571,677
- Yahuan Lou$5,077,989
- Charles S Cox$8,111,868
- Ralph S Freedman$885,116
Others in their field
Top investigators on “Immunoprophylaxis”
- Peter B. Gilbert · Fred Hutchinson Cancer Center$115,163,901
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$79,984,108
- Mary A Staat · Children'S Hospital Med Ctr (Cincinnati)$15,643,196
- Ruth Margrit Ruprecht · Dana-Farber Cancer Institute$10,481,806
- Richard K. Plemper · Georgia State University$9,612,878
- Natasha Bassam Halasa · Vanderbilt University Medical Center$8,672,487
Research focus
ImmunoprophylaxisImmuneHomeostasisImmunologicsBaseAdoptive ImmunotherapyAutoimmune ProcessAllogenicHematopoietic NeoplasmsChronic Graft Versus Host DiseaseClinical ResearchClinical TreatmentClinical TrialsAutoimmune DiseasesEffective TherapyEngraftmentFitnessCell TherapyCell TransplantationAutoimmunityGenerationsGraft-Vs-Host DiseaseHematopoietic Cell TransplantationImmunosuppressive Agents
Grant awards (5)
Stability and potency of LAP+FOXP3+Tregs as novel cell therapy for GVHD$384,518
R01 · FY2016 · HL · contact PI
Stability and potency of LAP+FOXP3+Tregs as novel cell therapy for GVHD$378,628
R01 · FY2015 · HL · contact PI
Stability and potency of LAP+FOXP3+Tregs as novel cell therapy for GVHD$376,590
R01 · FY2014 · HL · contact PI
Stability and potency of LAP+FOXP3+Tregs as novel cell therapy for GVHD$359,206
R01 · FY2013 · HL · contact PI
Stability and potency of LAP+FOXP3+Tregs as novel cell therapy for GVHD$372,863
R01 · FY2012 · HL · contact PI